What's new for 'JKB_daily1' in PubMed

This message contains My NCBI what's new results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).
Do not reply directly to this message.

Sender's message: Sepsis or genomics or altitude: JKB_daily1

Sent on Tuesday, 2011 May 17
Search (sepsis[MeSH Terms] OR septic shock[MeSH Terms] OR altitude[MeSH Terms] OR genomics[MeSH Terms] OR genetics[MeSH Terms] OR retrotransposons[MeSH Terms] OR macrophage[MeSH Terms]) AND ("2009/8/8"[Publication Date] : "3000"[Publication Date]) AND (("Science"[Journal] OR "Nature"[Journal] OR "The New England journal of medicine"[Journal] OR "Lancet"[Journal] OR "Nature genetics"[Journal] OR "Nature medicine"[Journal]) OR (Hume DA[Author] OR Baillie JK[Author] OR Faulkner, Geoffrey J[Author]))
Click here to view complete results in PubMed. (Results may change over time.)
To unsubscribe from these e-mail updates click here.

PubMed Results

Items 1 - 5 of 5

1.	Nat Med. 2011 Mar;17(3):304-12. Taming the dragon: genomic biomarkers to individualize the treatment of cancer. Majewski IJ, Bernards R. Source Division of Molecular Carcinogenesis, Centre for Biomedical Genetics, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Abstract The gradual shift from cytotoxic drugs to highly selective, targeted therapeutic agents for cancer requires a parallel effort to characterize cancers at the molecular level to guide the choice of therapy for the individual patient. Here we review the genomic technologies that can be used to develop these drug response indicators, or biomarkers. We also discuss hurdles in their development and the implementation of biomarkers in clinical practice.
	PMID: 21386834 [PubMed - indexed for MEDLINE]
	Related citations

2.	Nat Med. 2011 Mar;17(3):297-303. Cancer genomics: from discovery science to personalized medicine. Chin L, Andersen JN, Futreal PA. Source Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. lynda_chin@dfci.harvard.edu Abstract Recent advances in genome technologies and the ensuing outpouring of genomic information related to cancer have accelerated the convergence of discovery science and clinical medicine. Successful examples of translating cancer genomics into therapeutics and diagnostics reinforce its potential to make possible personalized cancer medicine. However, the bottlenecks along the path of converting a genome discovery into a tangible clinical endpoint are numerous and formidable. In this Perspective, we emphasize the importance of establishing the biological relevance of a cancer genomic discovery in realizing its clinical potential and discuss some of the major obstacles to moving from the bench to the bedside.
	PMID: 21383744 [PubMed - indexed for MEDLINE]
	Related citations

< /tr>

3.	Nat Med. 2011 Mar;17(3):285-6. B cells and macrophages in cancer: yin and yang. Mantovani A.
	PMID: 21383737 [PubMed - indexed for MEDLINE]
	Related citations

4.	Nat Med. 2011 Mar;17(3):270. When it takes two to tango, FDA suggests a new regulatory dance. Dolgin E.
	PMID: 21383727 [PubMed - indexed for MEDLINE]
	Related citations

5.	Nat Med. 2011 Mar;17(3):262-5. A close look at cancer. Farrell A.
	PMID: 21383721 [PubMed - indexed for MEDLINE]
	Related citations